The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.
 
Jeffrey A. Meyerhardt
Honoraria - Cota Healthcare; Taiho Pharmaceutical
Consulting or Advisory Role - Array BioPharma
Research Funding - Boston Biomedical (Inst)
 
Qian Shi
Stock and Other Ownership Interests - Amgen; Johnson & Johnson
Consulting or Advisory Role - Yiviva
Research Funding - Celgene (Inst); Roche/Genentech (Inst)
 
Charles S. Fuchs
Leadership - CytomX Therapeutics
Stock and Other Ownership Interests - CytomX Therapeutics; Entrinsic Health; EvolveImmune Therapeutics
Consulting or Advisory Role - Agios; Amylin; Bain Capital; CytomX Therapeutics; Daiichi Sankyo; Entrinsic Health; EvolveImmune Therapeutics; Genentech/Roche; Lilly; Merck; Sanofi; Taiho Pharmaceutical; Unum Therapeutics
Expert Testimony - Amylin; Lilly
 
Donna Niedzwiecki
No Relationships to Disclose
 
Tyler J. Zemla
No Relationships to Disclose
 
Priya Kumthekar
Leadership - Vivacitas Oncology
Stock and Other Ownership Interests - Vivacitas Oncology
Consulting or Advisory Role - Abbvie; Orbus Therapeutics
Research Funding - Abbvie; DNAtrix; Genentech/Roche; Novocure; Orbus Therapeutics
Patents, Royalties, Other Intellectual Property - Utility patent for ANG 1005. No financial gain, no royalties.
 
Katherine A Guthrie
No Relationships to Disclose
 
Felix Couture
No Relationships to Disclose
 
J. Phillip Kuebler
Consulting or Advisory Role - Advarra
 
Johanna C. Bendell
Consulting or Advisory Role - Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cerulean Pharma (Inst); Continuum Clinical (Inst); Cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); Ipsen (Inst); Janssen (Inst); Kyn therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Moderna Therapeutics (Inst); Molecular Partners (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Phoenix Biotech (Inst); Prelude Therapeutics (Inst); Relay Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tanabe Research (Inst); TD2 (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tolero Pharmaceuticals (Inst); Torque (Inst)
Research Funding - Abbott/AbbVie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Agios (Inst); Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); Arcus Biosciences (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bellicum Pharmaceuticals (Inst); Bicycle Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Gritstone Bio (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); ImClone Systems (Inst); Incyte (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Jacobio (Inst); Janssen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Molecular Partners (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Pieris Pharmaceuticals (Inst); Prelude Therapeutics (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Rgenix (Inst); Sanofi (Inst); Seagen (Inst); Shattuck Labs (Inst); Sierra Oncology (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Torque (Inst); TRACON Pharma (Inst); Tyrogenex (Inst); Unum Therapeutics (Inst); Vyriad (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ARMO BioSciences; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; FORMA Therapeutics; Gilead Sciences; Ipsen; Lilly; MedImmune; Merck; Novartis; OncoMed; Roche/Genentech; Taiho Pharmaceutical
 
Pankaj Kumar
No Relationships to Disclose
 
DeQuincy Andrew Lewis
No Relationships to Disclose
 
Benjamin R. Tan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Merck Serono (Inst); Roche/Genentech (Inst); Sillajen (Inst); tyrogenex (Inst)
 
Monica M. Bertagnolli
Research Funding - Abbvie (Inst); Agenus (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer Health (Inst); Breast Cancer Research Foundation (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chinese Medical Education Association (Inst); Complion (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GHI Pharma (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Leidos (Inst); Leidos (Inst); Lexicon (Inst); Lilly (Inst); Massachusetts General Hospital (Inst); Matrex (Inst); Mayo Clinic (Inst); Merck (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); MITRE Corporation (Inst); Novartis (Inst); Patient-Centered Outcomes Research Institute (PCORI) (Inst); Pfizer (Inst); Pharmacyclics (Inst); Robert Wood Johnson Foundation (Inst); Sagerock Advisors (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Teva (Inst)
(OPTIONAL) Uncompensated Relationships - Leap Therapeutics; Syntalogic Pharmaceuticals; Syntimmune
 
Axel Grothey
Honoraria - Aptitude Health; Elsevier; IMEDEX
Consulting or Advisory Role - Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genentech/Roche; Lilly (Inst)
Research Funding - Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; Bayer; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche
 
Howard S. Hochster
Consulting or Advisory Role - Amgen; Bayer; Elion Oncology; Exelixis; Genentech
 
Richard M. Goldberg
Honoraria - Amgen
Consulting or Advisory Role - Merck; Merck KGaA; Novartis; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Amgen; Merck; Merck KGaA
 
Alan P. Venook
Consulting or Advisory Role - Bayer; Eisai; Halozyme; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
Travel, Accommodations, Expenses - Bayer; Genentech; Halozyme; Roche
 
Charles David Blanke
No Relationships to Disclose
 
Anthony Frank Shields
Consulting or Advisory Role - Caris Life Sciences; ImaginAb; TransTarget
Speakers' Bureau - Caris Life Sciences
Research Funding - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; H3 Biomedicine; Halozyme; ImaginAb; Incyte; Inovio Pharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Plexxikon; Taiho Pharmaceutical; Torque; Xencor
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget